Cognitive predictors of response to treatment for depression in multiple sclerosis

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 18, Issue 3, 2006, Pages 356-363

  Julian, Laura J ^a,b   Mohr, David C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; TASK PERFORMANCE; TREATMENT RESPONSE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; GROUP THERAPY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PREDICTION AND FORECASTING; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDEPRESSIVE AGENTS; COGNITION; COGNITIVE THERAPY; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY, GROUP;

EID: 85047683609     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2006.18.3.356     Document Type: Article

References (44)

1. Sadovnick AD, Remick RA, Allen J, et al: Depression and multiple sclerosis. Neurology 1996; 46:628-632
2. Patten SB, Beck CA, Williams JV, et al: Major depression in multiple sclerosis: a population-based perspective. Neurology 2003; 61:1524-1527
3. McIntosh-Michaelis SA, Roberts MH, Wilkinson SM, et al: The prevalence of cognitive impairment in a community survey of multiple sclerosis. Br J Clin Psychol 1991; 30(pt 4):333-348
4. Arnett PA, Higginson CI, Randolph JJ: Depression in multiple sclerosis: relationship to planning ability. J Int Neuropsychol Soc 2001; 7:665-674
5. Arnett PA, Higginson CI, Voss WD, et al. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology 1999; 13:546-556
6. Pakenham KI: Adjustment to multiple sclerosis: application of a stress and coping model. Health Psychol 1999; 18:383-392
7. Feinstein A, Roy P, Lobaugh N, et al: Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004; 62:586-590
8. Bakshi R, Czarnecki D, Shaikh ZA, et al: Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 2000; 11:1153-1158
9. Pujol J, Bello J, Deus J, et al: Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 1997; 49:1105-1110
10. Zorzon M, de Masi R, Nasuelli D, et al: Depression and anxiety in multiple sclerosis: a clinical and MRI study in 95 subjects. J Neurol 2001; 248:416-421
11. Zorzon M, Zivadinov R, Nasuelli D, et al. Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol 2002; 9:491-496
12. Mohr DC, Epstein L, Luks TL, et al: Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. J Consult Clin Psychol 2003; 71:1017-1024
13. Schiffer RB, Babigian HM: Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis: an epidemiologic study. Arch Neurol 1984; 41:1067-1069
14. Alexopoulos GS, Meyers BS, Young RC, et al: Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000; 57:285-290
15. Alexopoulos GS, Kiosses DN, Murphy C, et al: Executive dysfunction, heart disease burden, and remission of geriatric depression. Neuropsychopharmacology 2004; 29:2278-2284
16. Kalayam B, Alexopoulos GS: Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999; 56:713-718
17. Potter GG, Kittinger JD, Wagner HR, et al: Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology 2004; 29:2266-2271
18. Dunkin JJ, Leuchter AF, Cook IA, et al: Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 2000; 60:13-23
19. Tekin S, Cummings JL: Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 2002; 53:647-654
20. Mayberg HS, Brannan SK, Mahurin RK, et al: Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997; 8:1057-1061
21. Mayberg HS: Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997; 9:471-481
22. Mohr DC, Boudewyn AC, Huang L, et al: Comparative outcome trial of three treatments for depression in multiple sclerosis. Ann Behav Med 2000; 22(suppl):S123
23. Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-231
24. First MD, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for the DSM-IV Axis I Disorders, patient ed. (SCID - I/P), Version 2.0. New York, State Psychiatric Institute, 1995
25. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
26. Beck AT, Steer RA: Manual for the Beck Depression Inventory. San Antonio, Psychological Corporation, 1993
27. Beck, JS: Cognitive Therapy: Basics and Beyond. New York, NY, Guilford, 1995
28. Spiegel D, Kimerling R: Group psychotherapy for women with breast cancer: relationships among social support, emotional expression, and survival, in Emotion, Social Relationships, and Health. Edited by Ryff C, Singer BH. Oxford University Press, London, 2001, pp 97-123
29. Scott TF, Nussbaum P, McConnell H, et al: Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995; 17:421-422
30. Lezak MD: Neuropsychological Assessment, 2nd Ed. New York, Oxford University Press, 1983
31. Rao SM, Leo GJ, Ellington L, et al: Cognitive dysfunction in multiple sclerosis, II, impact on employment and social functioning. Neurology 1991; 41:692-696
32. Spreen, O, Strauss, E: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, Second Ed. Oxford New York, Oxford University Press, 1998
33. Dodrill CB: A neuropsychological battery for epilepsy. Epilepsia 1978; 19:611-623
34. Hauser SL, Dawson DM, Lehrich JR, et al: Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308:173-180
35. Committee for Proprietary Medicinal Products (CPMP): Points to consider on adjustment for baseline covariates. Stat Med 2004; 23:701-709
36. Alexopoulos GS, Kiosses DN, Choi SJ, et al: Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am J Psychiatry 2002; 159:1929-1932
37. Kampf-Sherf O, Zlotogorski Z, Gilboa A, et al: Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. J Affect Disord 2004; 82:453-459
38. Soares JC, Mann JJ: The anatomy of mood disorders - review of structural neuroimaging studies. Biol Psychiatry 1997; 41:86-106
39. Mead LA, Mayer AR, Bobholz JA, et al: Neural basis of the Stroop interference task: response competition or selective attention? J Int Neuropsychol Soc 2002; 8:735-742
40. Goldapple K, Segal Z, Garson C, et al: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61:34-41
41. Helgeson VS, Cohen S, Schulz R, et al: Group support interventions for women with breast cancer: who benefits from what? Health Psychol 2000; 19:107-114
42. Drevets WC, Price JL, Simpson JR, et al: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386:824-827
43. Vlassenko A, Sheline YI, Fischer K, et al: Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. J Neuropsychiatry Clin Neurosci 2004; 16:360-363
44. Holthoff VA, Beuthien-Baumann B, Zundorf G, et al: Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatr Scand 2004; 110:184-194